MRNA CANCER VACCINE

Russia Develops a Personalized Cancer Vaccine
After years of research, Russia has officially developed a tested and trusted personalized cancer vaccine — and it’s changing everything we thought we knew about cancer care.

Russian researchers, led by the Gamaleya National Research Center, with the help of other medical research centers have developed a tested and trusted mRNA-based personalized cancer vaccine designed to activate the patient’s own immune system to identify and destroy cancer cells.

What makes this vaccine unique?

It is not a general preventive vaccine, but a custom therapeutic tool tailored to each patient.

Using genomic sequencing, scientists identify tumor-specific mutations (neoantigens) from the patient’s cancer cells.

The vaccine delivers synthetic mRNA encoding these antigens to the body, enabling the immune system—especially T-cells—to specifically recognize and eliminate tumor cells.

Tested and Trusted:

Successfully demonstrated tumor suppression and metastasis prevention in preclinical trials.

Human clinical trials are scheduled to begin in late 2025, with a primary focus on melanoma and other solid tumors.

The vaccine leverages platforms proven in the development of the Sputnik V COVID-19 vaccine.

Potential Impact:

A major step forward in personalized medicine and immuno-oncology.

A new treatment option for patients with advanced or treatment-resistant cancers.

Positioned to become a global model in the application of AI and mRNA technology in cancer therapy.

Estimated production cost per vaccine: \~300,000 rubles (\~USD \$2,800) Per shot
Government-funded in Russia**: Free to patients under the national healthcare system
Potential export to **friendly nations or clinical partners, which has been approvals

For more enquires please contact our customer service.